IN2012DE01792A - - Google Patents

Download PDF

Info

Publication number
IN2012DE01792A
IN2012DE01792A IN1792DE2012A IN2012DE01792A IN 2012DE01792 A IN2012DE01792 A IN 2012DE01792A IN 1792DE2012 A IN1792DE2012 A IN 1792DE2012A IN 2012DE01792 A IN2012DE01792 A IN 2012DE01792A
Authority
IN
India
Prior art keywords
formulation
cancer cells
cells
genes
glycolipids
Prior art date
Application number
Other languages
English (en)
Inventor
Roy Sayantani
Banerjee Rajkumar
Prasad Chakrabarti Pradosh
Badari Narayana Prasad Rachapudi
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Priority to PCT/IN2013/000368 priority Critical patent/WO2013186793A1/en
Priority to US14/406,895 priority patent/US9763881B2/en
Priority to IN1792DE2012 priority patent/IN2012DE01792A/en
Publication of IN2012DE01792A publication Critical patent/IN2012DE01792A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN1792DE2012 2012-06-11 2013-06-11 IN2012DE01792A (cs)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/IN2013/000368 WO2013186793A1 (en) 2012-06-11 2013-06-11 Rice bran-lipids based formulation and process for preparation thereof for selective delivery of genes to cancer cells
US14/406,895 US9763881B2 (en) 2012-06-11 2013-06-11 Rice bran-lipids based formulation and process for preparation thereof for selective delivery of genes to cancer cells
IN1792DE2012 IN2012DE01792A (cs) 2012-06-11 2013-06-11

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1792DE2012 IN2012DE01792A (cs) 2012-06-11 2013-06-11

Publications (1)

Publication Number Publication Date
IN2012DE01792A true IN2012DE01792A (cs) 2015-10-16

Family

ID=48856905

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1792DE2012 IN2012DE01792A (cs) 2012-06-11 2013-06-11

Country Status (3)

Country Link
US (1) US9763881B2 (cs)
IN (1) IN2012DE01792A (cs)
WO (1) WO2013186793A1 (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118458A1 (en) * 2017-12-11 2019-06-20 Respirogen, Inc. Devices and methods for delivery of oxygen to a wound

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692593B1 (fr) 1992-06-18 1995-06-16 Inst Francais Du Petrole Procede de production de sophorolipides acetyles sous leur forme acide a partir d'un substrat consistant et une huile ou un ester.
JPH10152498A (ja) 1996-09-27 1998-06-09 Kanebo Ltd 糖脂質誘導体、それを有効成分とする免疫抑制剤およびその製造用中間体
JP4454051B2 (ja) 1997-01-24 2010-04-21 東洋水産株式会社 新規な糖脂質、その製造方法及びその用途
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
EP0893493A3 (de) 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
ZA988333B (en) 1997-09-12 1999-03-23 Brigham & Woman S Hospital Synthetic antigens for CD1-restricted immune responses
US5871714A (en) 1997-10-16 1999-02-16 Pharmacal Biotechnologies, Inc. Compositions for controlling bacterial colonization
US6333433B1 (en) 1998-11-09 2001-12-25 Council Of Scientific Industrial Research Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkl group for intracellular delivery of biologically active molecules
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
US6953849B2 (en) 2001-03-28 2005-10-11 Council Of Scientific And Industrial Research Process for the isolation of glycolipids
EP1938843A1 (en) * 2006-12-19 2008-07-02 Novosom AG Lipids and lipid assemblies comrising transfection enhancer elements

Also Published As

Publication number Publication date
WO2013186793A9 (en) 2014-05-01
US9763881B2 (en) 2017-09-19
US20150164797A1 (en) 2015-06-18
WO2013186793A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
MX2015014423A (es) Administración efectiva de genes grandes por vectores aav duales.
ZA202103233B (en) Lipid nanoparticle formulations
AU2015329974A8 (en) GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
EP3698631A3 (en) Methods of delivering oligonucleotides to immune cells
NZ700075A (en) Trialkyl cationic lipids and methods of use thereof
EP4241767A3 (en) Novel lipids and compositions for the delivery of therapeutics
MX341332B (es) Lipidos biodegradables para la administracion de agentes activos.
PH12015500431B1 (en) Glucosylceramide synthase inhibitors
MY171561A (en) Conjugates for treating diseases caused by psma expressing cells
HK1206645A1 (en) Ionizable cationic lipids
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
PH12013500513A1 (en) Nanocapsules containing microemulsions
WO2012129394A3 (en) Methods and compositions for the treatment of cancer
MX354618B (es) Sistema de nanopartículas nts-poliplex para terapia génica de cáncer.
WO2013028942A8 (en) Targeting microbubbles
EA032867B9 (ru) Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты
IN2014MN01886A (cs)
WO2014167126A3 (en) Platform for targeted delivery to stem cells and tumor cells and uses thereof
TN2014000322A1 (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX2017014641A (es) Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
SG10201806064XA (en) Anti-tumor compositions and methods
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
MX2011010763A (es) Promotor de planta operable en endosperma y usos del mismo.
IN2012DE01792A (cs)